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Abstract
Background: Warfarin is an oral anticoagulant (OAT) that needs active management to ensure
therapeutic range. Initial management is often carried out as an inpatient, though not requiring
inpatient facilities. This mismatch results in financial costs which could be directed more
efficaciously. The extent of this has previously been unknown. Here we aim to calculate the
potential number of bed nights which may be saved among those being dose optimized as inpatients
and examine associated factors.
Methods: A 6 week prospective audit of inpatients receiving OAT, at Cork University Hospital,
was carried out. The study period was from 11th June 2007 to 20th July 2007. Data was collected
from patient's medications prescription charts, medical record files, and computerised haematology
laboratory records. The indications for OAT, the patient laboratory coagulation results and
therapeutic intervals along with patient demographics were analysed. The level of potentially
avoidable inpatient nights in those receiving OAT in hospital was calculated and the potential cost
savings quantified. Potential avoidable bed nights were defined as patients remaining in hospital for
the purpose of optimizing OAT dosage, while receiving subtherapeutic or therapeutic OAT (being
titred up to therapeutic levels) and co-administered covering low molecular weight heparin, and
requiring no other active care. The average cost of €638 was taken as the per night hospital stay
cost for a non-Intensive Care bed. Ethical approval was granted from the Ethical Committee of the
Cork Teaching Hospitals, Cork, Ireland.
Results: A total of 158 patients were included in the audit. There was 94 men (59.4%) and 64
women (40.6%). The mean age was 67.8 years, with a median age of 70 years.
Atrial Fibrillation (43%, n = 70), followed by aortic valve replacement (15%, n = 23) and pulmonary
emboli (11%, n = 18) were the commonest reasons for prescribing OAT. 54% had previously been
prescribed OAT prior to current admission.
It was confirmed that, there are potentially avoidable nights in patients receiving OAT. The majority
of this group were those being commenced on OAT for the first time (p = 0.00002), in the
specialities of Cardiology, Cardiothoracic surgery and Care of the Elderly. The potential number
of bed nights to be saved is 13 per week for the hospital or 1.1 bed nights per 10,000 general
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BMC Research Notes 2009, 2:41 http://www.biomedcentral.com/1756-0500/2/41hospital admissions. These were predominantly weekday nights. The estimated cost of avoidable
inpatient OAT dose optimization was approximately €8300 per week.
Conclusion: With rising costs and the increasing demands for acute hospital beds, alterations to
inpatient management for this group of patients should be considered. Alternatives include
increasing the size of current anticoagulation clinics, introduction of POCT (point of care testing)
devices and increased GP management. POCT can be justified based upon the publication by
Gardiner et al, who showed that 87% of patients find self testing straightforward, 87% were
confident in the result they obtained using the devices and 77% preferred self testing.
Background
Warfarin, a Vitamin K antagonist, is the most commonly
prescribed oral anticoagulant therapy (OAT). Patients tak-
ing this OAT must have regular coagulation measure-
ments to assess appropriate OAT dosage. Subtherapeutic
anticoagulation can result in thrombosis, which can be
life-threatening, while supratherapeutic anticoagulation
can result in haemorrhage, which can also be fatal. The
commonest indications for OAT are prevention of arterial
thromboembolism in patients with atrial fibrillation and/
or mechanical heart valves and treatment and prevention
of deep vein thrombosis and pulmonary emboli. Dura-
tion of treatment varies, from 6 weeks to 6 months in
venous thrombosis, to lifelong therapy in cardiac indica-
tions or recurrent thrombosis. The risk of haemorrhage on
long-term OAT varies between 1 and 15% per annum and
the risk of death increases with increasing coagulation,
accepting that death may be due to co-morbidity, an ele-
vated coagulation status being an indicator of end stage
disease [1].
It is the opinion of the authors that patients are often
needlessly kept in hospital as inpatients solely for the pur-
pose of optimizing OAT to achieve adequate anticoagula-
tion. This service does not require inpatient facilities and
thus a mismatch of services to requirement is occurring,
with financial consequences. Alternatives to this inpatient
management are to increase the facilities of the hospitals
current anticoagulation clinics, introduction of point of
care testing (POCT) devices and increase General Practi-
tioner management of OAT. This study aims to confirm
and quantify patients remaining as inpatients solely for
the purpose of optimizing OAT dosage.
Methods
A 6 week prospective audit of all inpatients receiving OAT,
at Cork University Hospital, a hospital with approxi-
mately 27,000 annual inpatient admissions, was carried
out. The study period was from 11th June 2007 to 20th July
2007. The study period was selected to include 3 weeks
pre and post doctor change over. Note 1st July is the
changeover date for new non-consultant hospital doctors.
Data was collected from patient's medications prescrip-
tion charts, medical record files, and computerised hae-
matology laboratory records. The indications for OAT,
patient laboratory coagulation results and therapeutic
intervals along with patient demographics were recorded
by a single data recorder researcher and analysed. On
patient discharge, contact was made with the primary
admission team and patient records were reviewed by the
single data recorder researcher, to establish if the patient
had spent potentially avoidable nights, solely due to OAT
management. Judgement regarding potentially avoidable
nights was made by the single data recorder researcher on
review of patient medical files. Pre-specified criteria for a
potentially avoidable bed night was defined as a patient
remaining in hospital for the purpose of optimizing OAT
dosage, while receiving subtherapeutic (being titred up to
therapeutic levels) or therapeutic OAT and co-adminis-
tered covering low molecular weight heparin, and requir-
ing no other active care. Primary admission teams'
opinions were also recorded.
The level of potentially avoidable inpatient nights in
those receiving OAT was calculated and the potential cost
savings quantified. The average cost of €638 was taken as
the per night hospital stay cost for a non-Intensive Care
Unit bed in our hospital. Data analysis was carried out
using SPSS.
Ethical approval was granted from the hospital's Quality
of Research Department and the Ethical Committee of the
Cork Teaching Hospitals, Cork, Ireland. Informed consent
was received from participants.
Results
A total of 158 patients received OAT as an inpatient dur-
ing the study period. There were 94 men (59.4%) and 64
women (40.6%), with a mean age of 67.8 years (median
= 70). 54% (n = 86) were prescribed OAT prior to study
period admission, of which 68% (n = 59) had a therapeu-
tic anticoagulation status on admission.
The commonest reasons for prescribing OAT, among the
cohort, was Atrial fibrillation (43%, n = 70), followed by
atrial valve replacement (15%, n = 23), pulmonary embo-Page 2 of 5
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cerebrovascular accidents (3%, n = 4). Therefore, under-
standably, the specialties of Cardiothoracic Surgery, Car-
diology and Care of the Elderly were the biggest
prescribers of OAT, comprising 46% (73/158) of cases
(20%, n = 31; 17%, n = 27; 9%, n = 15 respectively).
On review of patient's medications prescription charts,
medical record files, and computerised haematology lab-
oratory records, a total of 26 patients (26/158 = 16.5%)
were noted to have at least one potentially avoidable night
in hospital due to OAT dosage optimization alone. The
potentially avoidable bed nights for these patients totals
78 beds in the 6 weeks, with a mean of 3 potentially
avoidable nights per patient (median = 2, mode = 2). Of
interest there was a statistically significant relationship
between whether the patient was newly prescribed OAT (n
= 72) or previously had OAT prescribed prior to study
admission (n = 86), and whether they spend potentially
avoidable nights in hospital. 86.7% of patients treated
with OAT prior to admission spent no potentially avoida-
ble nights in hospital whereas 52.9% of the new OAT
patients spent a potentially avoidable night in hospital (p-
value = 0.00004). Of those patients who spent potentially
avoidable nights in hospital for OAT dosage optimiza-
tion, 58% (15/26) spent at least one weekend night as an
inpatient, i.e. a Saturday and/or Sunday night. The major-
ity of avoidable nights were during the week, 73% (57/
78). Of the 86 existing OAT prescribed patients, 36% were
therapeutic or achieved optimization of their OAT (up
10% upon their admission) by discharge, while of the 72
new patients discharged 34% were therapeutic. The
median, mode and mean number of coagulation blood
test measurements taken in hospital for the cohort were 8,
9 and 9.62 respectively.
The mean stay of the cohort patients was 12.9 days
(median = 10, mode = 9), with the mean stay of patients
who spent a potentially avoidable night of 13.7 days
(median = 10.5, mode = 6).
Regards a doctor/team perspective on avoidable nights,
admitting team doctors reported that in 16.5% (26/158)
of cases they felt that there was at least one potentially
avoidable night in hospital as a consequence of inpatient
OAT dosage optimization. These 26 cases highlighted by
treating doctors coincided with all of the 26 cases found
by the single data recorder researcher. Variations were
seen in pre and post the 1st July (changeover date for new
non-consultant hospital doctors). Pre 1st July, 21% (n =
15) of cases had at least one potentially avoidable night in
hospital for the purpose of OAT dosage optimization,
compared to 12.5% (n = 11) in the three weeks post 1st
July changeover.
Discussion
From the findings of this study one may draw the conclu-
sion that there are potentially avoidable nights in those
initiated on OAT in hospital. In this study, avoidable hos-
pital nights occurred in 26 out of 158 patients. These
nights totalled 13 per week or 676 a year. The average care
cost per non-ICU bed for the hospital is €638, giving cost
of €8300 per week, and therefore these beds are worth
managing more efficaciously.
Of the 26 patients who spent potentially avoidable nights
in hospital, 15 had at least one night occurring at the
weekend. Although the majority of the potentially avoid-
able nights did occur during the week, some are occurring
at the weekend. This is a time when no active elective
medical management is taking place, re-enforcing the
point that these nights are avoidable both for patient and
hospital.
By looking at the other variables, it was found that it is a
specific sub-population of OAT receiving patients that
make up the majority of those 26 patients. 18 out of the
26 patients were newly prescribed OAT on their current
admission. Significantly more potentially avoidable
nights were required for patients new to OAT (p =
0.00004). When taken in addition to the result that the 3
biggest contributing departments (Cardiothoracic Sur-
gery, Cardiology and Care of the Elderly) comprise 46% of
the study cohort, the majority of the OAT prescribed pop-
ulation in question can be identified. This makes targeting
changes easier.
Taking the average number of inpatients nights in the
total population versus those that could have gone home
earlier there is a small difference of 2.4 days (12.9 days
vs.10.5 days). The mean number of potentially avoidable
nights is 3 per patient. So an average stay of 10.5 days
minus average potentially avoidably stay of 3 days equals
almost a third of these patients inpatients duration may
be avoidable.
Of the 86 patients who had previous experience of OAT,
26% were therapeutic on admission, while on their dis-
charge 36% were therapeutic (up 10% upon their admis-
sion). It can be seen that of the 72 new patients discharged
only 34% were therapeutic. Although no correlation
between therapeutic on admission/discharge with poten-
tially avoidable nights was found, it gives a baseline to
which the efficacy of OAT is being managed, and thus
allowing re-audits in the future a point of reference. Out
of a mean 10 coagulation blood test measurements taken
in hospital per patient 7 were sub-therapeutic.
For the management of OAT receiving patients other
options include the expansion of the anticoagulation clin-Page 3 of 5
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This must be carried out within a means which would be
financially appropriate. One issue to this may be the qual-
ity of the continuity of care. If these patients are to be
managed effectively in an outpatient manner then the
requests of the hospital based teams need to be, both
clearly documented and freely available to our out-patient
colleagues. The value of this has been shown by an Amer-
ican study which showed that patients with a work up
error were 6.2 times more likely to be re-hospitalised
within 3 months [2]. This work-up error is when an out-
patient test or procedure suggested or scheduled by the
inpatient provider was not adequately provided by the
outpatient provider [2] i.e. a coagulation blood test check
and resultant change of OAT dose. This need for better
coordination and a systematic approach can also be rein-
forced from the findings of the study by van Walraven C
and colleagues which found that patients from commu-
nity practices showed significantly worse anticoagulation
control than those from anticoagulation clinics [3]. The
Anticoagulation Forum in the United States also feels that
a systematic approach is the key to anticoagulation man-
agement [4].
Another option, to avoid inpatient OAT dosage optimiza-
tion, is further devolution of management to GPs. The
acceptance of such responsibility is dependant on those
practitioners being knowledgeable and confident that
their practice has the abilities to deliver such a service,
along with being aware of hospital requests and formu-
lated patient specific protocols. In a study of Norwegian
GPs, gross variations in practice were noted along with an
unrealistically high risk of severe bleeding when faced
with the management of a moderately high INR anticoag-
ulation measurements of 5.9 [5]. This could explain our
primary care givers reluctance to take over management of
warfarin patients [6]. Computer dose calculation pro-
grams are available and this along with training in OAT
management will lead to an effective outlet to save on
costs due to avoidable inpatient stays.
The final option is POCT devices. These devices are attrac-
tive due to their superior efficacy in terms of time spent
therapeutic versus routine care, as well as lower incidence
of adverse events recorded [7-9]. Not every patient is suit-
able but, in who are, mainly long term OAT patients who
remain stable, it is a welcome therapeutic option [7]. Out
of every 100 eligible patients approximately 14 would be
able to conduct long-term self monitoring [8]. A locally
carried out randomised controlled trial, which remains
unpublished, took 163 patients from the same hospital
and combined anticoagulation management service AMS
with the POCT devices. The patients self-tested and logged
onto the internet and were advised of dose. If therapeutic
they were automatically provided algorithm-derived dos-
ing and repeat testing instructions. Those with non-thera-
peutic results were prioritized for pharmacist review.
Gardiner et al suggest that 87% of patients find self testing
straightforward, 87% were confident in the result they
obtained using the devices and 77% preferred self testing
[10].
From a financial perspective Boucher M and colleagues
have shown that converting from inpatient to outpatient
treatment of the condition of a proximal DVT was associ-
ated with a significant cost savings for their Canadian
institution, with no apparent compromise in patient care
noted [11].
Despite all of the above leaning towards the complete ini-
tiation and management of OAT in the OPD setting, in
certain circumstances inpatient initiation of OAT is rec-
ommend in the inpatient setting. The reason for such is
when there are poor links between community and hospi-
tal systems and the risk of adverse events to OAT are high,
such as in patients with a history of alcohol abuse, chronic
renal insufficiency, and a previous gastrointestinal bleed
[12]. Each case should be dealt with individually, but if
good links between inpatient and outpatient services exist
and there is minimal adverse event risk outpatient care of
OAT should be strongly considered.
Conclusion
Despite patients being kept in hospital, for many nights,
solely for OAT dosage optimization, many are still dis-
charged with subtherapeutic levels.
With rising costs and the increasing demands for acute
hospital beds, alterations to inpatient management for
this group of patients should be considered. Alternatives
include increasing the size of current anticoagulation clin-
ics, introduction of POCT devices and increased GP man-
agement. POCT can be justified based upon Gardiner et
al, who showed that 87% of patients find self testing
straightforward, 87% were confident in the result they
obtained using the devices and 77% preferred self testing.
In our hospital there is a potential to save approximately
1.1 bed nights per 10,000 general hospital admissions or
€8300 per week, should an alternative to inpatient OAT
dosage optimization be achieved.
Future work including a re-audit after implementation of
recommended changes would be advisable. As this is a
single centre study the authors would recommend a mul-
ticenter study over a longer study period to verify results.
It is hoped this study will act as a starting point for more
in-depth research in this area of medicine.Page 4 of 5
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